These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38507964)

  • 1. Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China.
    Zhang DS; Bao XP; Zhu JJ; Zheng WJ; Sun LX
    Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116253. PubMed ID: 38507964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China.
    Zhang MX; Zhang TT; Shi GF; Cheng FM; Zheng YM; Tung TH; Chen HX
    Expert Rev Vaccines; 2021 Jul; 20(7):891-898. PubMed ID: 33929930
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
    Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
    Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
    Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Actual Status of Hospitals as COVID-19 Vaccination Clinics in China and Safety Monitoring of Inactivated Vaccine: A Cross-Sectional Study.
    Huang J; Zhang MQ; Huang MZ; Lin GM
    Disaster Med Public Health Prep; 2022 Aug; 17():e256. PubMed ID: 36017705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
    Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
    Wan EYF; Chui CSL; Lai FTT; Chan EWY; Li X; Yan VKC; Gao L; Yu Q; Lam ICH; Chun RKC; Cowling BJ; Fong WC; Lau AYL; Mok VCT; Chan FLF; Lee CK; Chan LST; Lo D; Lau KK; Hung IFN; Leung GM; Wong ICK
    Lancet Infect Dis; 2022 Jan; 22(1):64-72. PubMed ID: 34411532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines.
    Durusu Tanriover M; Altuntas Aydin O; Guner R; Yildiz O; Celik I; Kose S; Akhan S; Akalin EH; Ozdarendeli A; Unal S; Ates I; Kara A;
    Hum Vaccin Immunother; 2024 Dec; 20(1):2346388. PubMed ID: 38924774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following immunization of elderly with COVID-19 inactivated virus vaccine (CoronaVac) in Southeastern Brazil: an active surveillance study.
    Miyaji KT; Itto LYU; Jacintho LC; Sales ACR; Hiratsuka M; Leonel FC; Higa-Taniguchi KT; Picone CM; Lara AN; Rodrigues CCM; Lopes MH; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e56. PubMed ID: 36197371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac®) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.
    Yang H; Li Z; Zhang R; Guo S; Wang B; Fang X; Zhang D; Zhang X; Tong Y; Wang Q; Deng Q; Sun Z; Liu X; Gao Y
    Vaccine; 2023 Feb; 41(7):1354-1361. PubMed ID: 36658045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
    J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects after COVID-19 vaccinations among residents of Poland.
    Andrzejczak-Grządko S; Czudy Z; Donderska M
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events following immunization of COVID-19 vaccine among children aged 6-11 years.
    Puspitarani F; Sitaresmi MN; Ahmad RA
    Front Public Health; 2022; 10():999354. PubMed ID: 36388348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China.
    Shenyu W; Xiaoqian D; Bo C; Xuan D; Zeng W; Hangjie Z; Qianhui Z; Zhenzhen L; Chuanfu Y; Juan Y; Gang Z; Huakun L
    Vaccine; 2022 Aug; 40(36):5356-5365. PubMed ID: 35933275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse events following 771 doses of the inactivated and mRNA COVID-19 vaccines: A survey study among health care providers.
    Bostan E; Yel B; Karaduman A
    J Cosmet Dermatol; 2022 Sep; 21(9):3682-3688. PubMed ID: 35775860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
    Cheng Y; Li T; Zheng Y; Xu B; Bi Y; Hu Y; Zhou YH
    Hum Vaccin Immunother; 2022 Nov; 18(5):2064134. PubMed ID: 35452357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X
    Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.